Opposing neural effects of naltrexone on food reward and aversion: Implications for the treatment of obesity

Psychopharmacology

Volumn 231, Issue 22, 2014, Pages 4323-4335

  Murray, Elizabeth ^a   Brouwer, Sietske ^a   McCutcheon, Rob ^a   Harmer, Catherine J ^a   Cowen, Philip J ^a   McCabe, Ciara ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

Aversion; fMRI; Food; Naltrexone; Neuroimaging; Obesity; Opioid antagonism; Reward

Indexed keywords

NALTREXONE; PLACEBO; NARCOTIC ANTAGONIST;

ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ANTERIOR INSULA; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN REGION; CACAO; CAUDATE NUCLEUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG TARGETING; FEEDING BEHAVIOR; FEMALE; FOOD AVERSION; FOOD INTAKE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INSULA; MALE; NEUROIMAGING; OBESITY; RANDOMIZED CONTROLLED TRIAL; REWARD; SENSORY STIMULATION; STIMULUS RESPONSE; STRAWBERRY; VISUAL STIMULATION; AFFECT; BRAIN; BRAIN MAPPING; DRUG EFFECTS; FOOD; NUCLEAR MAGNETIC RESONANCE IMAGING; TASTE; YOUNG ADULT;

ADULT; AFFECT; BRAIN MAPPING; CEREBRUM; DOUBLE-BLIND METHOD; FEMALE; FOOD; HUMANS; MAGNETIC RESONANCE IMAGING; NALTREXONE; NARCOTIC ANTAGONISTS; OBESITY; REWARD; TASTE; YOUNG ADULT;

EID: 84919779806     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3573-7     Document Type: Article

References (109)

1. Alger SA, Schwalberg MD, Bigaouette JM, Michalek AV, Howard LJ (1991) Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. Am J Clin Nutr 53:865-871
2. Anders S, Lotze M, Erb M, Grodd W, Birbaumer N (2004) Brain activity underlying emotional valence and arousal: a response-related fMRI study. Hum Brain Mapp 23:200-209
3. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561-571
4. Belin D, Everitt BJ (2008) Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. Neuron 57:432-441
5. Bencherif B, Guarda AS, Colantuoni C, Ravert HT, Dannals RF, Frost JJ (2005) Regional mu-opioid receptor binding in insular cortex is decreased in bulimia nervosa and correlates inversely with fasting behavior. J Nucl Med 46:1349-1351
6. Billes SK, Greenway FL (2011) Combination therapy with naltrexone and bupropion for obesity. Expert Opin Pharmacother 12:1813-1826
7. Borras MC, Becerra L, Ploghaus A, Gostic JM, DaSilva A, Gonzalez RG, Borsook D (2004) fMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers. J Neurophysiol 91:2723-2733
8. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, Goodman JM, Kantor HL, Gastfriend DR, Riorden JP, Mathew RT, Rosen BR, Hyman SE (1997) Acute effects of cocaine on human brain activity and emotion. Neuron 19:591-611
9. Cambridge VC, Ziauddeen H, Nathan PJ, Subramaniam N, Dodds C, Chamberlain SR, Koch A, Maltby K, Skeggs AL, Napolitano A, Farooqi IS, Bullmore ET, Fletcher PC (2013) Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people. Biol Psychiatry 73:887-894
10. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706-1713
11. Colasanti A, Rabiner EA, Lingford-Hughes A, Nutt DJ (2011) Opioids and anxiety. J Psychopharmacol 25:1415-1433
12. Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D, Erritzoe D, Tziortzi AC, Reed LJ, Lingford-Hughes AR, Waldman AD, Schruers KR, Matthews PM, Gunn RN, Nutt DJ, Rabiner EA (2012) Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. Biol Psychiatry 72(5):371-377
13. Collins DL, Neelin P, Peters TM, Evans AC (1994) Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr 18:192-205
14. de Araujo IE, Kringelbach ML, Rolls ET, Hobden P (2003a) Representation of umami taste in the human brain. J Neurophysiol 90:313-319
15. de Araujo IE, Kringelbach ML, Rolls ET, McGlone F (2003b) Human cortical responses to water in the mouth, and the effects of thirst. J Neurophysiol 90:1865-1876
16. Dean AJ, Saunders JB, Jones RT, Young RM, Connor JP, Lawford BR (2006) Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. J Psychiatry Neurosci 31:38-45
17. Drewnowski A, Krahn DD, Demitrack MA, Nairn K, Gosnell BA (1992) Taste responses and preferences for sweet high-fat foods: evidence for opioid involvement. Physiol Behav 51:371-379
18. Drewnowski A, Krahn DD, Demitrack MA, Nairn K, Gosnell BA (1995) Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters. Am J Clin Nutr 61:1206-1212
19. Fantino M, Hosotte J, Apfelbaum M (1986) An opioid antagonist, naltrexone, reduces preference for sucrose in humans. Am J Physiol 251:R91-R96
20. Faurion A, Cerf B, Le Bihan D, Pillias AM (1998) fMRI study of taste cortical areas in humans. Ann N Y Acad Sci 855:535-545
21. Fawcett J, Clark DC, Scheftner WA, Gibbons RD (1983) Assessing anhedonia in psychiatric patients. Arch Gen Psychiatry 40:79-84
22. Filbey FM, Myers US, Dewitt S (2012) Reward circuit function in high BMI individuals with compulsive overeating: similarities with addiction. Neuroimage 63:1800-1806
23. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for DSM-IV axis I disorders: clinical version. American Psychiatric Press, Washington
24. Fitzgerald DA, Posse S, Moore GJ, Tancer ME, Nathan PJ, Phan KL (2004) Neural correlates of internally-generated disgust via autobiographical recall: a functional magnetic resonance imaging investigation. Neurosci Lett 370:91-96
25. Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC (1994) Assessing the significance of focal activations using their spatial extent. Hum Brain Mapp 1:214-220
26. Friston KJ, Glaser DE, Henson RN, Kiebel S, Phillips C, Ashburner J (2002) Classical and Bayesian inference in neuroimaging: applications. Neuroimage 16:484-512
27. Garavan H, Pankiewicz J, Bloom A, Cho JK, Sperry L, Ross TJ, Salmeron BJ, Risinger R, Kelley D, Stein EA (2000) Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am J Psychiatry 157:1789-1798
28. Garcia-Garcia I, Narberhaus A, Marques-Iturria I, Garolera M, Radoi A, Segura B, Pueyo R, Ariza M, Jurado MA (2013) Neural responses to visual food cues: insights from functional magnetic resonance imaging. Eur Eat Disord Rev 21:89-98
29. Garner DM, Olmsted MP, Bohr Y, Garfinkel PE (1982) The eating attitudes test: psychometric features and clinical correlates. Psychol Med 12:871-878
30. Ghitza UE, Preston KL, Epstein DH, Kuwabara H, Endres CJ, Bencherif B, Boyd SJ, Copersino ML, Frost JJ, Gorelick DA (2010) Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatients. Biol Psychiatry 68:697-703
31. Goldstein RZ, Volkow ND (2002) Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159:1642-1652
32. Good AJ, Westbrook RF (1995) Effects of a microinjection of morphine into the amygdala on the acquisition and expression of conditioned fear and hypoalgesia in rats. Behav Neurosci 109:631-641
33. Gorelick DA, Kim YK, Bencherif B, Boyd SJ, Nelson R, Copersino M, Endres CJ, Dannals RF, Frost JJ (2005) Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry 57:1573-1582
34. Gracely RH, Dubner R, Wolskee PJ, Deeter WR (1983) Placebo and naloxone can alter post-surgical pain by separate mechanisms. Nature 306:264-265
35. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E (2010) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376:595-605
36. Harmer CJ, Cowen PJ (2013) 'It's the way that you look at it' - a cognitive neuropsychological account of SSRI action in depression. Philos Trans R Soc Lond B Biol Sci 368:20120407
37. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583
38. Hetherington MM, Vervaet N, Blass E, Rolls BJ (1991) Failure of naltrexone to affect the pleasantness or intake of food. Pharmacol Biochem Behav 40:185-190
39. Hillemacher T, Heberlein A, Muschler MA, Bleich S, Frieling H (2011) Opioid modulators for alcohol dependence. Expert Opin Investig Drugs 20:1073-1086
40. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K (2013) Effects of naltrexone sustained-release/bupropion sustained release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 36(12):4022-4029
41. Horder J, Harmer CJ, Cowen PJ, McCabe C (2010) Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. Int J Neuropsychopharmacol: 1-11
42. Horder J, Browning M, Di Simplicio M, Cowen PJ, Harmer CJ (2012) Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. J Psychopharmacol 26:125-132
43. http://www.who.int/mediacentre/factsheets/fs311/en/ (2012) World Health organisation
44. Katsiki N, Hatzitolios AI, Mikhailidis DP (2011) Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? Ann Med 43:249-258
45. Keedwell PA, Andrew C, Williams SC, Brammer MJ, Phillips ML (2005) The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry 58:843-853
46. Kelley AE, Berridge KC (2002) The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 22:3306-3311
47. Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, Zhang M (2002) Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav 76:365-377
48. Knutson B, Adams CM, Fong GW, Hommer D (2001) Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci 21:RC159
49. Koppert W, Angst M, Alsheimer M, Sittl R, Albrecht S, Schuttler J, Schmelz M (2003) Naloxone provokes similar pain facilitation as observed after short-term infusion of remifentanil in humans. Pain 106:91-99
50. Koppert W, Filitz J, Troster A, Ihmsen H, Angst M, Flor H, Schuttler J, Schmelz M (2005) Activation of naloxone-sensitive and -insensitive inhibitory systems in a human pain model. J Pain 6:757-764
51. Kosten T, Silverman DG, Fleming J, Kosten TA, Gawin FH, Compton M, Jatlow P, Byck R (1992) Intravenous cocaine challenges during naltrexone maintenance: a preliminary study. Biol Psychiatry 32:543-548
52. Lee MW, Fujioka K (2009) Naltrexone for the treatment of obesity: review and update. Expert Opin Pharmacother 10:1841-1845
53. Liang NC, Bello NT, Moran TH (2013) Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations. Int J Obes (Lond) 37:272-278
54. Liberzon I, Zubieta JK, Fig LM, Phan KL, Koeppe RA, Taylor SF (2002) mu-Opioid receptors and limbic responses to aversive emotional stimuli. Proc Natl Acad Sci U S A 99:7084-7089
55. Lieberman MD, Cunningham WA (2009) Type I and Type II error concerns in fMRI research: re-balancing the scale. Soc Cogn Affect Neurosci 4:423-428
56. Littleton J, Zieglgansberger W (2003) Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 12(Suppl 1):S3-S11
57. Liu X, Hairston J, Schrier M, Fan J (2011) Common and distinct networks underlying reward valence and processing stages: a meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev 35:1219-1236
58. Makowski CT, Gwinn KM, Hurren KM (2011) Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obes Facts 4:489-494
59. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1987) Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci 7:2445-2464
60. Marrazzi MA, Kinzie J, Luby ED (1995) A detailed longitudinal analysis on the use of naltrexone in the treatment of bulimia. Int Clin Psychopharmacol 10:173-176
61. Mason BJ, Goodman AM, Dixon RM, Hameed MH, Hulot T, Wesnes K, Hunter JA, Boyeson MG (2002) A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 27:596-606
62. McCabe C, Cowen PJ, Harmer CJ (2009) Neural representation of reward in recovered depressed patients. Psychopharmacology (Berl) 205:667-677
63. McCabe C, Mishor Z, Cowen PJ, Harmer CJ (2010) Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry 67:439-445
64. McCabe C, Huber A, Harmer CJ, Cowen PJ (2011) The D2 antagonist sulpiride modulates the neural processing of both rewarding and aversive stimuli in healthy volunteers. Psychopharmacology (Berl) 217:271-278
65. McCabe C, Woffindale C, Harmer CJ, Cowen PJ (2012) Neural processing of reward and punishment in young people at increased familial risk of depression. Biol Psychiatry 1;72(7):588-594
66. McElroy SL, Guerdjikova AI, Kim DD, Burns C, Harris-Collazo R, Landbloom R, Dunayevich E (2013) Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study. Prim Care Companion CNS Disord 15
67. Migliori GB, Raviglione MC, Schaberg T, Davies PD, Zellweger JP, Grzemska M, Mihaescu T, Clancy L, Casali L (1999) Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J 14:978-992
68. Miotto K, McCann M, Basch J, Rawson R, Ling W (2002) Naltrexone and dysphoria: fact or myth? Am J Addict 11:151-160
69. Morrison SE, Salzman CD (2010) Re-valuing the amygdala. Curr Opin Neurobiol 20:221-230
70. Nathan PJ, Bullmore ET (2009) From taste hedonics to motivational drive: central mu-opioid receptors and binge-eating behaviour. Int J Neuropsychopharmacol 12:995-1008
71. Nathan PJ, O'Neill BV, Napolitano A, Bullmore ET (2011) Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther 17:490-505
72. Nathan PJ, Bush MA, Tao WX, Koch A, Davies KM, Maltby K, O'Neill BV, Napolitano A, Skeggs AL, Brooke AC, Richards DB, Williams PM, Bullmore ET (2012) Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the mu-opioid receptor inverse agonist GSK1521498. J Clin Pharmacol 52:1456-1467
73. Nielsen CK, Simms JA, Li R, Mill D, Yi H, Feduccia AA, Santos N, Bartlett SE (2012) delta-Opioid receptor function in the dorsal striatum plays a role in high levels of ethanol consumption in rats. J Neurosci 32:4540-4552
74. Nitschke JB, Sarinopoulos I, Mackiewicz KL, Schaefer HS, Davidson RJ (2006) Functional neuroanatomy of aversion and its anticipation. Neuroimage 29:106-116
75. Nogueiras R, Romero-Pico A, Vazquez MJ, Novelle MG, Lopez M, Dieguez C (2012) The opioid system and food intake: homeostatic and hedonic mechanisms. Obes Facts 5:196-207
76. O'Doherty J, Rolls ET, Francis S, Bowtell R, McGlone F (2001) Representation of pleasant and aversive taste in the human brain. J Neurophysiol 85:1315-1321
77. Oldfield RC (1971) The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9:97-113
78. Paton JJ, Belova MA, Morrison SE, Salzman CD (2006) The primate amygdala represents the positive and negative value of visual stimuli during learning. Nature 439:865-870
79. Pavlovic ZW, Cooper ML, Bodnar RJ (1996) Opioid antagonists in the periaqueductal gray inhibit morphine and beta-endorphin analgesia elicited from the amygdala of rats. Brain Res 741:13-26
80. Petrovic P, Pleger B, Seymour B, Kloppel S, De Martino B, Critchley H, Dolan RJ (2008) Blocking central opiate function modulates hedonic impact and anterior cingulate response to rewards and losses. J Neurosci 28:10509-10516
81. Porrino LJ, Lyons D, Smith HR, Daunais JB, Nader MA (2004) Cocaine self-administration produces a progressive involvement of limbic, association, and sensorimotor striatal domains. J Neurosci 24:3554-3562
82. Rabiner EA, Beaver J, Makwana A, Searle G, Long C, Nathan PJ, Newbould RD, Howard J, Miller SR, Bush MA, Hill S, Reiley R, Passchier J, Gunn RN, Matthews PM, Bullmore ET (2011) Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol Psychiatry 16(826-35):785
83. Rolls ET, McCabe C (2007) Enhanced affective brain representations of chocolate in cravers vs. non-cravers. Eur J Neurosci 26:1067-1076
84. Rolls BJ, Rolls ET, Rowe EA, Sweeney K (1981) Sensory specific satiety in man. Physiol Behav 27:137-142
85. Rolls ET, Kringelbach ML, de Araujo IE (2003) Different representations of pleasant and unpleasant odours in the human brain. Eur J Neurosci 18:695-703
86. Sander D, Grafman J, Zalla T (2003) The human amygdala: an evolved system for relevance detection. Rev Neurosci 14:303-316
87. Schienle A, Schafer A, Hermann A, Vaitl D (2009) Binge-eating disorder: reward sensitivity and brain activation to images of food. Biol Psychiatry 65:654-661
88. Scinska A, Koros E, Polanowska E, Kukwa A, Bogucka-Bonikowska A, Kostowski W, Habrat B, Bienkowski P (2000) An opioid receptor antagonist, naltrexone, does not alter taste and smell responses in humans. Pol J Pharmacol 52:397-402
89. Sheth SA, Mian MK, Patel SR, Asaad WF, Williams ZM, Dougherty DD, Bush G, Eskandar EN (2012) Human dorsal anterior cingulate cortex neurons mediate ongoing behavioural adaptation. Nature 488:218-221
90. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P (1995) A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 167:99-103
91. Spetter MS, de Graaf C, Viergever MA, Smeets PA (2012) Anterior cingulate taste activation predicts ad libitum intake of sweet and savory drinks in healthy, normal-weight men. J Nutr 142:795-802
92. Stice E, Spoor S, Bohon C, Small DM (2008) Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science 322:449-452
93. Stice E, Yokum S, Bohon C, Marti N, Smolen A (2010) Reward circuitry responsivity to food predicts future increases in body mass: moderating effects of DRD2 and DRD4. Neuroimage 50:1618-1625
94. Stice E, Yokum S, Burger KS, Epstein LH, Small DM (2011) Youth at risk for obesity show greater activation of striatal and somatosensory regions to food. J Neurosci 31:4360-4366
95. Streeton C, Whelan G (2001) Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 36:544-552
96. Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Angrist B, Gatley SJ, Logan J, Ding YS, Pappas N (1999) Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry 156:19-26
97. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, Jayne M, Ma Y, Wong C (2006) Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 26:6583-6588
98. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F (2011) Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A 108:15037-15042
99. von Zerssen D, Strian F, Schwarz D (1974) Evaluation of depressive states, especially in longitudinal studies. Mod Probl Pharmacopsychiatry 7:189-202
100. Wacker J, Dillon DG, Pizzagalli DA (2009) The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia: integration of resting EEG, fMRI, and volumetric techniques. Neuroimage 46:327-337
101. Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, Kosslyn SM, Rose RM, Cohen JD (2004) Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 303:1162-1167
102. Wicker B, Keysers C, Plailly J, Royet JP, Gallese V, Rizzolatti G (2003) Both of us disgusted in My insula: the common neural basis of seeing and feeling disgust. Neuron 40:655-664
103. Wilson JL, Jenkinson M, de Araujo I, Kringelbach ML, Rolls ET, Jezzard P (2002) Fast, fully automated global and local magnetic field optimization for fMRI of the human brain. Neuroimage 17:967-976
104. Woolley JD, Lee BS, Taha SA, Fields HL (2007) Nucleus accumbens opioid signaling conditions short-term flavor preferences. Neuroscience 146:19-30
105. Yeomans MR, Gray RW (1996) Selective effects of naltrexone on food pleasantness and intake. Physiol Behav 60:439-446
106. Yeomans MR, Gray RW (2002) Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 26:713-728
107. Yeomans MR, Wright P (1991) Lower pleasantness of palatable foods in nalmefene-treated human volunteers. Appetite 16:249-259
108. Zald DH, Hagen MC, Pardo JV (2002) Neural correlates of tasting concentrated quinine and sugar solutions. J Neurophysiol 87:1068-1075
109. Ziauddeen H, Chamberlain SR, Nathan PJ, Koch A, Maltby K, Bush M, Tao WX, Napolitano A, Skeggs AL, Brooke AC, Cheke L, Clayton NS, Sadaf Farooqi I, O'Rahilly S, Waterworth D, Song K, Hosking L, Richards DB, Fletcher PC, Bullmore ET (2013) Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects. Mol Psychiatry 18:1287-1293